Infant Bacterial Therapeutics AB (IBT.B) AI Stock Analysis

• Market Cap: kr674.92M
• Dividend Yield: N/A
• Average Volume (3M): 6.66K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.01
• Revenue Growth: N/A
• EPS Growth: -2.51%
• Country: SE
• Employees: 8
• Sector: Healthcare
• Sector Strength: 37
• Industry: Biotechnology
• EPS (TTM): -1.24
• Shares Outstanding: 13,018,137
• 10 Day Avg. Volume: 6,580
• 30 Day Avg. Volume: 6,655
• PEG Ratio: -0.64
• Price to Book (P/B): 4.26
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -5.05
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 44 Neutral
• Price Target: ―

Infant Bacterial Therapeutics AB's overall stock score is primarily impacted by its financial struggles, particularly in profitability and cash flow, despite a strong balance sheet. The technical analysis suggests a bearish trend, further weighing on the score. Valuation remains a concern with a negative P/E ratio and no dividend yield.

Infant Bacterial Therapeutics AB Business Overview & Revenue Model

Company Description

Infant Bacterial Therapeutics AB (IBT.B) is a Swedish biopharmaceutical company focused on developing and commercializing drugs to prevent or treat diseases affecting premature infants. The company operates primarily in the healthcare and biotechnology sectors, with a core emphasis on leveraging its expertise in bacterial therapy to address unmet medical needs in neonatology. Its leading product candidate, IBP-9414, targets the prevention of necrotizing enterocolitis (NEC) in preterm infants, aiming to provide innovative solutions to improve infant health outcomes.

How the Company Makes Money

Infant Bacterial Therapeutics AB generates revenue primarily through the development and commercialization of its pharmaceutical products. The company's revenue model is centered around licensing agreements, research and development collaborations, and eventual sales of its therapeutic products once they receive regulatory approval. Key revenue streams include upfront payments, milestone payments, and royalties from partners involved in the commercialization and distribution of its products. Significant partnerships with larger pharmaceutical companies or research institutions can also contribute to its earnings, providing access to additional resources and markets, which is crucial for advancing its product pipeline and achieving commercial success.

Infant Bacterial Therapeutics AB Financial Statement Overview

Summary

Infant Bacterial Therapeutics AB exhibits a mixed financial profile. While the company has a strong equity position and no debt, it struggles with profitability and cash flow, highlighted by negative margins and declining cash flow metrics. The significant revenue increase is overshadowed by large operating losses, posing a risk to financial sustainability. The balance sheet remains a point of strength, but operational and cash flow improvements are needed to enhance overall financial health.

Income Statement

The company shows significant volatility in revenue growth, with total revenue drastically increasing from 77,000 to 5,000 in TTM. Despite this, gross profit margin remains strong at 100% due to the nature of the revenue. However, the net profit margin is negative due to substantial operating losses, indicating ongoing profitability challenges. Both EBIT and EBITDA margins are also severely negative, reflecting operating inefficiencies.

Balance Sheet

The balance sheet is relatively strong with no debt, resulting in a debt-to-equity ratio of zero. However, the ROE is negative due to continual net losses, suggesting poor returns on equity. The equity ratio remains robust, indicating a solid equity position relative to total assets, which provides some financial stability.

Cash Flow

The company faces significant cash flow challenges, with negative operating and free cash flows throughout. This is further exacerbated by a negative free cash flow growth rate, indicating worsening cash flow conditions. The operating cash flow to net income ratio is negative, highlighting the struggle to convert net income into cash.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	77.00K	12.00K	0.00	0.00
Gross Profit	0.00	77.00K	12.00K	0.00	0.00
EBITDA	-136.91M	11.55M	-65.45M	-44.99M	-72.01M
Net Income	-136.91M	-123.07M	-65.09M	-45.40M	-72.31M
Balance Sheet
Total Assets	239.57M	351.33M	349.62M	408.48M	450.32M
Cash, Cash Equivalents and Short-Term Investments	223.39M	329.06M	335.84M	386.75M	423.44M
Total Debt	0.00	0.00	0.00	0.00	0.00
Total Liabilities	69.30M	46.18M	17.91M	13.22M	10.16M
Stockholders Equity	170.26M	305.15M	331.71M	395.25M	440.15M
Cash Flow
Free Cash Flow	-113.13M	-101.22M	-85.80M	-55.62M	-58.39M
Operating Cash Flow	-113.13M	-101.22M	-85.80M	-55.62M	-58.39M
Investing Cash Flow	0.00	-4.15M	-1.00K	0.00	0.00
Financing Cash Flow	2.01M	96.52M	1.88M	91.00K	1.76M

Infant Bacterial Therapeutics AB Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 48.50
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:IBT.B, the sentiment is Positive. The current price of 48.5 is below the 20-day moving average (MA) of 48.90, below the 50-day MA of 53.42, and above the 200-day MA of 46.09, indicating a neutral trend. The MACD of -0.75 indicates Negative momentum. The RSI at 49.25 is Neutral, neither overbought nor oversold. The STOCH value of 30.51 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:IBT.B.

Infant Bacterial Therapeutics AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SANION	69 Neutral	€1.29B	4.84	152.78%	―	1533.99%	―
Sector *	52 Neutral	kr5.63B	10.07	-63.86%	1.97%	27.19%	26.73%
SYNACT	48 Neutral	kr995.50M	―	-48.22%	―	―	67.70%
XSPRAY	47 Neutral	kr1.94B	―	-42.24%	―	―	-19.44%
IBT.B	44 Neutral	kr674.92M	―	-57.38%	―	―	-2.51%
IRLAB.A	38 Underperform	kr287.29M	―	-194.31%	―	1643.36%	50.36%
CANTA	31 Underperform	€786.86M	―	-167.55%	―	―	46.67%